Literature DB >> 8986534

Expression of epidermal growth factor-related proteins and epidermal growth factor receptor in common epithelial ovarian tumors.

H Niikura1, H Sasano, S Sato, A Yajima.   

Abstract

The biologic significance of epidermal growth factor (EGF)-related proteins and EGF receptor (EGFR) in the development and progression of human ovarian carcinoma was studied in 7 ovarian cystadenomas, 6 mucinous tumors of low malignant potential (LMP), and 25 invasive adenocarcinomas by immunohistochemistry. Results were correlated with clinicopathologic features. We also examined immunoreactivity in five serous adenocarcinomas both before and after cisplatin chemotherapy. Amphiregulin (AR) expression was observed only in mucinous tumors (4 of 8 cystadenomas, 2 of 6 tumors of LMP, and 6 of 10 cystadenocarcinomas), but was not detected in the serous tumors or clear cell adenocarcinomas. EGF, cripto, and EGFR expression was significantly higher in mucinous cystadenocarcinomas than in mucinous cystadenomas or mucinous tumors of LMP. Three of five specimens obtained at a second operation after chemotherapy had more intense or diffuse immunostaining for transforming growth factor alpha (TGF-alpha) than the initial specimens did. Coexpression of more than two of the EGF-related proteins or EGFR significantly correlated with increased surgical stage in serous and clear cell carcinoma. AR expression seems to correlate with mucinous differentiation rather than with advanced stages of ovarian tumors. Our results indicate that expression of some EGF-related proteins is greater in certain subtypes of ovarian carcinomas than in their benign counterparts and that coexpression of these proteins is associated with advanced stage in serous and clear cell carcinoma. Increased TGF-alpha expression may also be related to ovarian tumor resistance to cisplatin chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8986534     DOI: 10.1097/00004347-199701000-00010

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  21 in total

1.  A multivariate model of ErbB network composition predicts ovarian cancer cell response to canertinib.

Authors:  Rexxi D Prasasya; Kang Z Vang; Pamela K Kreeger
Journal:  Biotechnol Bioeng       Date:  2011-08-23       Impact factor: 4.530

Review 2.  Proteomics and biomarkers in clinical trials for drug development.

Authors:  Jung-min Lee; Jasmine J Han; Gary Altwerger; Elise C Kohn
Journal:  J Proteomics       Date:  2011-05-04       Impact factor: 4.044

3.  The epidermal growth factor receptor responsive miR-125a represses mesenchymal morphology in ovarian cancer cells.

Authors:  Karen D Cowden Dahl; Richard Dahl; Jessica N Kruichak; Laurie G Hudson
Journal:  Neoplasia       Date:  2009-11       Impact factor: 5.715

4.  Hydrogen peroxide mediates EGF-induced down-regulation of E-cadherin expression via p38 MAPK and snail in human ovarian cancer cells.

Authors:  Jung-Chien Cheng; Christian Klausen; Peter C K Leung
Journal:  Mol Endocrinol       Date:  2010-07-07

5.  Relevant molecular markers and targets.

Authors:  Kathleen M Darcy; Russel J Schilder
Journal:  Gynecol Oncol       Date:  2006-10-10       Impact factor: 5.482

6.  The coupling of epidermal growth factor receptor down regulation by 1alpha,25-dihydroxyvitamin D3 to the hormone-induced cell cycle arrest at the G1-S checkpoint in ovarian cancer cells.

Authors:  Zheng Shen; Xiaohui Zhang; Jinfu Tang; Ravi Kasiappan; Umesh Jinwal; Pengfei Li; Shan Hann; Santo V Nicosia; Jie Wu; Xiaohong Zhang; Wenlong Bai
Journal:  Mol Cell Endocrinol       Date:  2011-03-30       Impact factor: 4.102

7.  PEA3 is necessary for optimal epidermal growth factor receptor-stimulated matrix metalloproteinase expression and invasion of ovarian tumor cells.

Authors:  Karen D Cowden Dahl; Reema Zeineldin; Laurie G Hudson
Journal:  Mol Cancer Res       Date:  2007-05-02       Impact factor: 5.852

Review 8.  Activated epidermal growth factor receptor in ovarian cancer.

Authors:  Laurie G Hudson; Reema Zeineldin; Melina Silberberg; M Sharon Stack
Journal:  Cancer Treat Res       Date:  2009

9.  Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia.

Authors:  Halla S Nimeiri; Amit M Oza; Robert J Morgan; Gregory Friberg; Kristen Kasza; Leonardo Faoro; Ravi Salgia; Walter M Stadler; Everett E Vokes; Gini F Fleming
Journal:  Gynecol Oncol       Date:  2008-04-18       Impact factor: 5.482

10.  Gene expression patterns in the histopathological classification of epithelial ovarian cancer.

Authors:  Honglan Zhu; Jing Jie Yu
Journal:  Exp Ther Med       Date:  2010-01-01       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.